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The Klotho protein, whose gene has predominant renal expression, acts in the control of
serum phosphorus and 1,25-dihydroxyvitamin D3 and regulates the function of ion chan-
nels. It also participates in the mechanism of protection against oxidative stress and acts on
the  vascular endothelium by inducing the production of nitric oxide. Mutations that reﬂect
defects in the Klotho gene expression may be implicated in the onset of osteonecrosis, pri-
apism, and leg ulcers in patients with sickle cell disease, as a result of oxidative stress and
endothelial impairment, important factors in the development and severity of this disease.
Previous reports regarding the association of Klotho single nucleotide polymorphisms with
sickle  cell disease subphenotypes have found that these polymorphisms are important to
identify genetic markers of risk in these individuals and allow early and more effective
therapeutic intervention.© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
Multiple aging phenotypes result from defects in gene
11Introduction
Klotho is a gene that consists of ﬁve exons and is located
on chromosome 13q12 in humans. Its expression occurs pre-
dominantly in the kidney distal convoluted tubules and the
choroid plexus of the brain. Endocrine organs (pituitary gland,
parathyroid gland, pancreas, ovary, testis and placenta), the
heart and pancreatic  cells also express Klotho.1–7Klotho generates two transcripts, a transmembrane pro-
tein and a secreted protein, resulting from alternative splicing
to the third exon. Additionally, the transmembrane protein
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reserved.can be cleaved by - and -secretases to generate a secreted
protein, which is, two-times longer than the alternatively
spliced transcript.4,6,8–11 So, the effects of the Klotho protein
extend beyond the tissues that express the gene because of its
humoral factor function. Klotho reaches the systemic circula-
tion by secreted fractions, and is released into the extracellular
space and subsequently into circulation; it is found in blood,
urine and cerebrospinal ﬂuid (Figure 1).11–13ão Oswaldo Cruz (FIOCRUZ), Rua Waldemar Falcão, 121, Candeal,
expression of Klotho, such as growth retardation, hyper-
phosphatemia, moderate hypercalcemia, vascular and soft
tissue calciﬁcation, and high levels of 1,25-dihydroxyvitamin
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – Transmembrane and secreted Klotho protein processing. The transmembrane Klotho protein acts as a co-receptor
for ﬁbroblast growth factor 23 signaling. This transmembrane protein forms complexes with Na+/K+-ATPase channels and
is recruited to the cell surface. Once on the surface, the Klotho protein is cleaved by secretases forming a soluble form of
Klotho. This form enters the circulatory system similar to the form produced by alternative splicing, and acts on other
organs as a humoral factor.
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m3 (1.25(OH)2D3) and ﬁbroblast growth factor 23 (FGF23). These
efects in animals result in a shortened life expectancy when
ompared to wild-type phenotypes. Additionally, the kl−/− ani-
al  exhibits hypokinesia, gait changes, and atrophy of the
enitals, skin and thymus.3,14 Klotho single nucleotide poly-
orphisms (SNPs) have been associated with subphenotypes
f sickle cell disease (SCA),15–19 a monogenic autosomal reces-
ive disorder, characterized by a -globin gene (HBB) mutation
hich results in the formation of the S variant hemoglobin
Hb S).
Given the possible role of Klotho as one of the genes respon-
ible for the phenotypic variability between patients with
ickle cell disease (SCD), the aim of this paper is to review
he various features of the Klotho protein, as well as discuss
urrent literature about the association between Klotho poly-
orphisms and SCD subphenotypes.Klotho  participates  in  the  regulation  of  the
bone-kidney  endocrine  axis
The phenotypic similarity between kl−/− mice and mice
with reduced Fgf23 expression (Fgf23−/− mice) suggests a
functional relationship between Klotho and FGF23. The
Klotho transmembrane protein is a required co-factor/co-
receptor for FGF23 signaling (Figure 1), and the inactivation
of the Klotho-FGF23 axis in kl−/−/Fgf23−/− mice results in
increased expression of co-transporter sodium-phosphate
type-2a (NaPi-2a).14 FGF23, in turn, is a bone-derived hor-
mone that acts by inhibiting kidney phosphate reabsorption
and vitamin D biosynthesis. FGF23, incorporated into the
ternary complex of FGF23-FGFR-Klotho, inhibits NaPi-2a activ-
ity, increasing phosphaturic activity. Therefore, FGF23 and
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Figure 2 – Phosphate and vitamin D homeostasis
regulation. Vitamin D upon binding to its vitamin D
receptor (VDR) in osteocytes induces VDR-retinoid X
receptor (RXR) heterodimer binding, which activates Fgf23
expression. Phosphate also induces a similar reaction.
FGF23 then binds to the FGFR-Klotho complex in renal
tubular cells, blocking phosphate reabsorption by NaPi-2a
transporters and vitamin D synthesis by suppressing the
Cyp27b1 expression and upregulating Cyp24 expression.
This mechanism controls the phosphate and vitamin D
levels in the body; the Fgf23 expression increases when the
levels of these two factors are elevated. After
re-establishing normal levels, Fgf23 expression is
downregulated and maintains phosphate reabsorption and
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Figure 3 – Soluble Klotho protein acts on phosphate
transport in the proximal tubules. In acute regulatory
conditions, Klotho modiﬁes an unknown substrate, glycan
(1), reducing the phosphate transporter coupled to sodium
(2). Additionally, the carrier undergoes proteolytic cleavage
(3) and subsequent endocytosis (4). Upon sustained
elevated soluble Klotho levels or chronic regulation
conditions, there is ongoing reduction of these transporters
at the cell surface.
2vitamin D synthesis.
Klotho act on the bone-kidney endocrine axis to maintain
phosphate homeostasis (Figure 2).4,14,20,21
This bone-kidney endocrine axis also regulates vitamin D
levels. High serum phosphate levels increase Fgf23 expres-
sion in the bone. FGF23 represses Cyp27b1 expression and
increases Cyp24 expression, reducing 1-hydroxylase levels.
The end result is the reduction of 1.25(OH)2D3 serum syn-
thesis (Figure 2). These mechanisms are essential for vitamin
D homeostasis, preventing hypervitaminosis D. It has also
been found that the administration of 1.25(OH)2D3 induces the
expression of Klotho in the kidney, which reinforces the inte-
grated mechanism between FGF23 and Klotho in this axis.4,22
Disturbances of these negative feedback loops can also lead
to a hypercalcemic state because vitamin D also promotes gut
calcium absorption.4,23,24
From observations of Fgf23−/− mice, there is additional
phosphaturic activity from secreted Klotho protein that is
FGF23 independent. The Klotho glycosidase activity acts on an
unknown substrate that is present in the brush border of kid-
ney proximal tubular cells. This modiﬁcation is accompanied
by proteolytic cleavage (this step occurs, but it is not required
to inactivate the transporter) and NaPi-2a co-transporter inter-
nalization (Figure 3).2
Klotho can also inhibit phosphate transport in vascular
smooth muscle cells through NaPi class 3 transporters, Pit-
1 and Pit-2, preventing vascular calciﬁcation events, because
excessive phosphate inﬂux in these cells promotes a cascade
of events responsible for the calcium and phosphate mineral-
ization in their interior.25Adapted from Hu et al.
Effect  of  the  Klotho  protein  on  ion  channel
regulation
The secreted Klotho protein regulates other ion channels, such
as the transient receptor potential cation channel, member 5
of subfamily V (TRPV5), which is primarily responsible for Ca2+
entry during kidney transepithelial reabsorption. Secreted
Klotho protein inhibits TRPV5 internalization through its siali-
dase activity on this ion channel, increasing TRPV5 cell surface
levels and with this the Ca2+ inﬂow and kidney reabsorption
(Figure 4).4,26,27
The retaining mechanism of the cell surface ion channel
occurs during the regulation of potassium channels in the kid-
ney outer medulla (ROMK1), resulting in an increase in ROMK1
in the plasma membrane of renal tubular cells, with increased
potassium secretion in urine.28
Klotho  as  an  insulin/growth  factor  insulin-like
1  signaling  mechanism  regulator
Klotho protein is associated with insulin/growth factor
insulin-like 1 (IGF-1) signaling pathway regulation, which
results in oxidative stress suppression. Transcription factors
known as nuclear mammalian forkhead box O (FOXO) are fac-
tors that directly bind to antioxidant enzyme promoters, such
as catalase and mitochondrial manganese-superoxide dismu-
tase (SOD2), inducing enzyme expression. As a result, there is
increased removal of reactive oxygen species (ROS), confer-
ring oxidative stress resistance. These FOXOs are negatively
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Figure 4 – General model for TRPV5 regulation by Klotho. Soluble Klotho removes the sialic acid residue attached by 2.6
bonding in the N-acetyl-lactosamine (LacNAc) repeats of the TRPV5 N-glycans. The LacNAc, when exposed, can bind to its
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uigand, the galectin-1 dimer, in the extracellular matrix. This
egulated by enabling insulin/IGF-1 signaling, which promotes
he serine-threonine kinase Akt phosphorylation. The Akt
as the ability to phosphorylate FOXO, resulting in its exclu-
ion from the nucleus and inactivation. Klotho protein acts
y inhibiting insulin/IGF-1 signaling, decreasing FOXO phos-
horylation and increasing SOD2 expression and minimizing
xidative stress.11,29
ffect  of  Klotho  protein  on  the  vascular
ndothelium
oth secreted Klotho proteins have anti-apoptotic and anti-
ging activity on vascular endothelial cells. These cells
re continuously exposed to Klotho. The vascular endothe-
ium, due to the release of nitric oxide (NO) in response
o speciﬁc agonists such as acetylcholine, plays an impor-
ant role in vascular tone maintenance. It has been shown
hat mutations in the Klotho gene signiﬁcantly attenuate
ndothelium-dependent vasodilation of the aorta and arteri-
30,31les in response to acetylcholine. There is evidence that
lotho in the secreted and membrane bound forms can up-
egulate NO production, although the mechanisms are still
nknown.4,11 It is believed that defects in the Klotho genechanism reduces carrier internalization.
down-regulate endothelium NO synthase (eNOS). The effects
of Klotho on the vascular endothelium are protective against
endothelial dysfunction.
Kl−/− mice subjected to the induction of lower limb
ischemia exhibited persistent blood ﬂow loss and decreased
capillary capacity, in contrast to the high perfusion observed
in heterozygous Klotho animals (kl+/−) and wild-type ani-
mals. Kl−/− animals present with deﬁcient angiogenesis and
reduced levels of urinary NO and tissue cyclic guanosine
monophosphate (cGMP), with high rates of progression to
spontaneous amputation.32 Moreover, the Klotho protein is
capable of increasing angiotensin-converting enzyme-I activ-
ity in endothelial cells by the activation of the cyclic adenosine
monophosphate (cAMP)-protein kinase A (PKA) pathway,33
suggesting involvement of the renin-angiotensin system and
NO in vascular tone maintenance.
The Klotho protein has an anti-apoptotic effect on human
umbilical vein endothelial cells, with decreased caspase-3
and caspase-9 activity, therefore acting as a humoral factor.
It retards cellular aging by mechanisms involving p53/p21.34Furthermore, from its ability to bind several members of
the Wnt  family, Klotho can suppress biological activity,
working as an antagonist to prevent accelerated cellular
aging.13
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Table 1 – A list of Klotho SNPs signiﬁcantly associated
with sickle cell disease subphenotypes.
SNP Subphenotypes References
rs211234 Osteonecrosis Baldwin et al.15
rs211235 Osteonecrosis Baldwin et al.15
rs211239 Osteonecrosis Baldwin et al.15
rs211239 Priapism Nolan et al.17
rs2149860 Osteonecrosis Baldwin et al.15
rs2149860 Leg ulcers Nolan et al.18
rs2249358 Priapism Nolan et al.17
rs480780 Osteonecrosis Baldwin et al.15
rs499091 Osteonecrosis Baldwin et al.15
rs516306 Osteonecrosis Baldwin et al.15
rs516306 Leg ulcers Nolan et al.18
rs565587 Osteonecrosis Baldwin et al.15
rs576404 Osteonecrosis Baldwin et al.15
rs685417 Osteonecrosis Baldwin et al.15
Sickle cell disease
• Hemolysis
• Increases oxidative stress
• Decreases NO production 
• Chronic inflammation
• Homeostatic imbalance
• Vasoocclusive phenomena
• Increases oxidative stress
• Decreases NO production
Osteonecrosis
priapism
leg ulcer
klotho SNPs
Figure 5 – Summary of the role of Klotho SNPs to establishrs685417 Leg ulcers Nolan et al.18
The Klotho protein has been assessed as a therapeutic tool
in particular in respect to preventing activity of age-related
phenotypes.30,35,36 The main aim of this review is to describe
the possible role of the Klotho protein as a biomarker in sickle
cell disease.
Klotho  protein  in  sickle  cell  disease
Some studies have evaluated the association of Klotho SNPs
with subphenotypes of individuals with SCA, one type of
SCD.15–19 It is a disorder of monogenic autosomal recessive
inheritance, characterized by a mutation in the HBB gene,
where valine replaces glutamic acid in the -globin polypep-
tide chain. This mutation results in the variant hemoglobin
named S (Hb S), which, under deoxygenated conditions, tends
to polymerize inside the red blood cell conferring a sickle
shape.
These individuals exhibit a chronic inﬂammatory and
hemolytic state, with signiﬁcant production of ROS, increased
molecule adhesion of endothelial cells and blood cells,
and reduced NO production resulting in vaso-occlusive
phenomena; all of these are important events that trigger
the varied subphenotypes of the disease.37 The large pheno-
typic variability observed in SCD (including pain crises, stroke,
priapism, osteonecrosis, leg ulcers, bacteremia, pulmonary
hypertension, acute chest syndrome, and gallstones) demon-
strates gene interactions in subphenotype development.38
Individuals with SCA and osteonecrosis of the hip or shoul-
der, with or without -thalassemia, showed that 10 Klotho SNPs
were signiﬁcantly associated with these subphenotypes.15
Additionally, two SNPs have been associated with priapism17
and three with leg ulcers18 (Table 1). These associations may
be underestimated, given that control group individuals could
develop such subphenotypes in the future.
However, other studies have not succeeded in replicat-
ing these results. Ulug et al.19 tested Klotho SNPs in 39 SCD
patients who  had femoral and humeral head avascular necro-
sis, evidenced by symptoms and imaging studies. The controls
were 205 individuals with SCD without symptoms of this
subphenotype. There was no reproduction of the associationSCD subphenotypes.
found by Baldwin et al.15 which may be explained by the inad-
equate sample size and by the absence of any radiological
investigation of controls as it is not possible to ensure that
the control individuals were not asymptomatic patients in
early stages of avascular necrosis. Elliotte et al.16 tested the
association of Klotho SNPs and priapism in SCD patients, but
were unsuccessful in ﬁnding the association between SNPs
and subphenotypes reported by Nolan et al.17 probably due
to differences in the deﬁnition of priapism, the patients’ ages
and adjustments made in the tests.
Osteonecrosis, associated with vaso-occlusive events and
increased blood viscosity, is a common clinical manifesta-
tion of SCD. Bone microcirculation is a favorable environment
for sickled red blood cells, leukocytes, and platelet deposi-
tion, leading to infarction and necrosis of bone tissue.38,39
So, despite the methodological differences that did not allow
reproducibility of the results of Baldwin et al.15 it may be that
endothelial dysfunction is exacerbated in individuals with
SCD and Klotho SNPs due to the loss of the protective effect
against oxidative stress as well as reductions in the production
of NO that affect vascular tone.
Priapism is a prolonged penile erection irrespective of
sexual interest, and has a direct relation with intravas-
cular hemolysis.38 Normal erection is dependent on the
activation of guanylate cyclase by NO for the synthesis of
cGMP, which generates the rapid relaxation of penile smooth
muscle. Erection regulation is driven by phosphodiesterase
type 5, which controls the production of cGMP.40,41 How-
ever, the expression of phosphodiesterase type 5 is reduced
when there is NO depletion. Both hemolysis and genetic
alterations in Klotho expression contribute to the reduction
in NO synthesis, which affects the erection control mech-
anisms by phosphodiesterase type 5, thereby prolonging
erection.
Similar to priapism, leg ulcers are related to the severity of
hemolysis, and both NO depletion and oxidative stress appear
to play a role in the development of ulcers.18,38 However, the
pathophysiology of this clinical event still needs to be eluci-
dated in order to clarify whether these mechanisms cause leg
ulcers when Klotho SNPs are present.
Figure 5 summarizes the role of Klotho SNPs to establish the
SCD subphenotypes.
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onclusion
he Klotho gene has a wide range of functions in several
tructures of the body, increasing phosphaturic activity and
educing 1.25(OH)2D3 synthesis, regulating ion channel lev-
ls on the cell surface with anti-aging and anti-apoptotic
ffects, reducing oxidative stress and inducing the produc-
ion of NO. SNPs in this gene have reportedly been associated
ith subphenotypes of SCD, however this data was not repro-
uced probably due to methodological differences. Given the
ndothelial involvement of the Klotho protein and knowl-
dge about SCD pathophysiology (markedly centered around
emolysis and vaso-occlusive phenomena), it is essential to
onduct further studies with the power needed to test the
ssociations between the Klotho gene and SCD, in order to
dentify genetic markers of risk in these individuals and allow
arlier and more  effective therapeutic interventions.
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